Smoking remains the primary preventable cause of death in the United States and throughout the world. Smoking cessation represents a significant unmet medical need. It represents a $3 Billion opportunity in the US alone.
Currently available smoking cessation medications have nonselective mechanisms of action and are not very successful, with cessation rates of only 15–40%. , the newest and most effective smoking cessation medication is varenicline (Chantix®), which is an α4β2 nAChR partial agonist. Even though varenicline is the best smoking cessation medication available , opportunities exist for improvement. Product labeling warns of potentially serious neuropsychiatric side effects that can result in significant problems in patients, An effective new therapeutic could make not only improve the health of people who smoke, but reduce the economic burden of smoking and its related health diseases.